GB202005599D0 - Modulation of t cell cytotoxicity and related therapy - Google Patents

Modulation of t cell cytotoxicity and related therapy

Info

Publication number
GB202005599D0
GB202005599D0 GBGB2005599.2A GB202005599A GB202005599D0 GB 202005599 D0 GB202005599 D0 GB 202005599D0 GB 202005599 A GB202005599 A GB 202005599A GB 202005599 D0 GB202005599 D0 GB 202005599D0
Authority
GB
United Kingdom
Prior art keywords
modulation
cell cytotoxicity
related therapy
therapy
cytotoxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2005599.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London filed Critical University College London
Priority to GBGB2005599.2A priority Critical patent/GB202005599D0/en
Publication of GB202005599D0 publication Critical patent/GB202005599D0/en
Priority to CN202180041305.5A priority patent/CN115697357A/zh
Priority to PCT/EP2021/059989 priority patent/WO2021209627A1/en
Priority to EP21721004.6A priority patent/EP4135725A1/en
Priority to US17/919,135 priority patent/US20230158073A1/en
Priority to CA3175622A priority patent/CA3175622A1/en
Priority to IL297309A priority patent/IL297309A/en
Priority to KR1020227039985A priority patent/KR20230004643A/ko
Priority to MX2022012924A priority patent/MX2022012924A/es
Priority to AU2021255917A priority patent/AU2021255917A1/en
Priority to JP2022562684A priority patent/JP2023521436A/ja
Priority to BR112022020819A priority patent/BR112022020819A2/pt
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
GBGB2005599.2A 2020-04-17 2020-04-17 Modulation of t cell cytotoxicity and related therapy Ceased GB202005599D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB2005599.2A GB202005599D0 (en) 2020-04-17 2020-04-17 Modulation of t cell cytotoxicity and related therapy
BR112022020819A BR112022020819A2 (pt) 2020-04-17 2021-04-16 Modulação de citotoxicidade de célula t e terapia relacionada
US17/919,135 US20230158073A1 (en) 2020-04-17 2021-04-16 Modulation of t cell cytotoxicity and related therapy
PCT/EP2021/059989 WO2021209627A1 (en) 2020-04-17 2021-04-16 Modulation of t cell cytotoxicity and related therapy
EP21721004.6A EP4135725A1 (en) 2020-04-17 2021-04-16 Modulation of t cell cytotoxicity and related therapy
CN202180041305.5A CN115697357A (zh) 2020-04-17 2021-04-16 T细胞细胞毒性的调节和相关治疗
CA3175622A CA3175622A1 (en) 2020-04-17 2021-04-16 Modulation of t cell cytotoxicity and related therapy
IL297309A IL297309A (en) 2020-04-17 2021-04-16 Modulation of T-cell cytotoxicity and related therapy
KR1020227039985A KR20230004643A (ko) 2020-04-17 2021-04-16 T 세포 세포독성의 조정 및 관련 요법
MX2022012924A MX2022012924A (es) 2020-04-17 2021-04-16 Modulacion de citotoxicidad de celulas t y terapia relacionada.
AU2021255917A AU2021255917A1 (en) 2020-04-17 2021-04-16 Modulation of T cell cytotoxicity and related therapy
JP2022562684A JP2023521436A (ja) 2020-04-17 2021-04-16 Ｔ細胞細胞傷害性の調節および関連療法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2005599.2A GB202005599D0 (en) 2020-04-17 2020-04-17 Modulation of t cell cytotoxicity and related therapy

Publications (1)

Publication Number Publication Date
GB202005599D0 true GB202005599D0 (en) 2020-06-03

Family

ID=70859980

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2005599.2A Ceased GB202005599D0 (en) 2020-04-17 2020-04-17 Modulation of t cell cytotoxicity and related therapy

Country Status (12)

Country Link
US (1) US20230158073A1 (enExample)
EP (1) EP4135725A1 (enExample)
JP (1) JP2023521436A (enExample)
KR (1) KR20230004643A (enExample)
CN (1) CN115697357A (enExample)
AU (1) AU2021255917A1 (enExample)
BR (1) BR112022020819A2 (enExample)
CA (1) CA3175622A1 (enExample)
GB (1) GB202005599D0 (enExample)
IL (1) IL297309A (enExample)
MX (1) MX2022012924A (enExample)
WO (1) WO2021209627A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022061115A1 (en) * 2020-09-18 2022-03-24 Vor Biopharma Inc. Compositions and methods for cd7 modification
CN115058504B (zh) * 2022-07-14 2025-07-04 广州医科大学 膀胱癌th17 cd4+t细胞亚群及其特征基因与应用
WO2025063257A1 (ja) * 2023-09-22 2025-03-27 国立大学法人大阪大学 制御性ｔ細胞を製造する方法
GB202417285D0 (en) * 2024-11-25 2025-01-08 Univ Oxford Innovation Ltd Expanded t cell population

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP2014509841A (ja) 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法
KR20140060541A (ko) 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 rna 조작된 t 세포
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
AU2015330898B2 (en) * 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
CA2977106A1 (en) * 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
US12350349B2 (en) * 2016-08-03 2025-07-08 Washington University Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
WO2018106972A1 (en) * 2016-12-07 2018-06-14 La Jolla Institute For Allergy And Immunology Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
EP3606518A4 (en) * 2017-04-01 2021-04-07 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
US12226479B2 (en) * 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
CA3067244A1 (en) * 2017-06-12 2018-12-20 Children's Healthcare Of Atlanta, Inc. T-cell antigen targeted chimeric antigen receptor (car) and uses in cell therapies

Also Published As

Publication number Publication date
IL297309A (en) 2022-12-01
WO2021209627A1 (en) 2021-10-21
JP2023521436A (ja) 2023-05-24
US20230158073A1 (en) 2023-05-25
BR112022020819A2 (pt) 2022-11-29
MX2022012924A (es) 2023-04-03
CA3175622A1 (en) 2021-10-21
CN115697357A (zh) 2023-02-03
AU2021255917A1 (en) 2022-11-17
KR20230004643A (ko) 2023-01-06
EP4135725A1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
HUE072871T2 (hu) Akkumulátortok, akkumulátor, energiafelhasználó berendezés, és eljárás és berendezés akkumulátor elõállítására
IL314812B1 (en) Kras modulators and uses thereof
GB201909573D0 (en) Modulation of T cell cytotoxicity and related therapy
IL289597A (en) Designation and efficient synthesis of lipid-fluorescein conjugates for car-t cell therapy
IL320805B1 (en) Therapeutic uses of tirzepatide
IL304376A (en) Medical combination of il-2 variant immunoconjugates directed against pd-1 and fap/4-1bb binding molecules
GB2615478B (en) Therapeutic and prophylactic use of microorganisms
GB202108572D0 (en) Therapeutic compounds and their use
GB202019475D0 (en) Therapeutic compounds and their use
SG11202105215QA (en) Combination therapy of arms and natural killer cells
IL316654A (en) Preparation and uses of 7-azaindenoisoquinolines
IL279274B1 (en) Cardiac pacing combined with irreversible electroporation therapy
EP3898950A4 (en) PRODUCTION AND THERAPEUTIC USE OF STANDARD DOUBLE NEGATIVE T LYMPHOCYTES
IL311999A (en) New modulators of EHMT1 and EHMT2 and their therapeutic use
CA3286605A1 (en) Treatment of cachexia using fibroblast cells and products thereof
ZA202108165B (en) Application of kdm5a gene and atrx gene
IL320820A (en) Therapeutic combinations of captopril and ventocalix
HK40115486A (en) Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof
CA3273489A1 (en) Therapeutic combinations of capivasertib and venetoclax
CA3296952A1 (en) Oncology combination therapy and methods of use
CA3294266A1 (en) Oncology combination therapy and methods of use
GB202109087D0 (en) Therapeutic methods and devices
CA3300403A1 (en) Combination therapy and uses thereof
AU2023903793A0 (en) Combination therapy and uses thereof
AU2023902434A0 (en) Combination therapy and uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)